GBIO - Stock Analysis & Overview

About Generation Bio Co.

Biotechnology

Healthcare

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Generation Bio Co. Key Metrics

Market Cap: $186M
52 Weeks Low: $0.86
52 Weeks High: $4.65
P/B: 1.61x
P/E: -1.17x
P/S: 14.11x

Upcoming Events

GBIO Analyst Forecasts

‌

GBIO Financials

GBIO Income Statement Key Metrics

Revenue(TTM)13.17 M
Gross Profit(TTM)7.34 M
EBITDA(TTM)-107.98 M
Net Income(TTM)-158.43 M
EPS Diluted(TTM)-2.39

Decode GBIO's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

GBIO earnings and revenue history

Gross Profit Margin vs Peers

Profit margin ratio of GBIO (0.109) is higher than the average of its peers (-13.311).

Net Profit Margin vs Peers

Net profit margin ratio of GBIO (-21.445) is higher than the average of its peers (-162.910).

GBIO Return on Equity

See how efficiently GBIO generates profit for it's shareholders.

-62.33%

100

Poor

Average

Strong

Return on Equity vs Peers

Return on Equity ratio of GBIO (-0.623) is lower than the average of its peers (-0.551).

Return on Equity Growth

GBIO's Return on Equity has shown poor growth over the past 10 years, increasing by only 5.24%.

GBIO Revenue Growth

See how GBIO has grown it's revenue over the past 10 years.

‌

Revenue Growth

GBIO's revenue has grown significantly over the past 10 years, increasing by over 133.96%.

Generation Bio Co.

Page title

Section title